| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| HYALURONIDASE (Paeds) Mechanism of action: Extravasation antidote; proteolytic enzyme Ref: 44 Last update: 2023-04-16 |
Injection: 150 units/mL Available through Health Canada Special Access Program. A supply is kept in the pharmacy and may be used for any patient in the hospital (pharmacy is to track usage). |
Tissue Injury secondary to Extravasation: (by physician only) Draw up 0.2 mL of 150 Unit/mL into 4 or 5 one mL syringes. Inject 0.1-0.2 mL (15-30 units) subcutaneously or intradermally in 4 to 5 sites around the circumference of infiltrate, using a new needle with each injection. Wait 10 to 15 minutes and inject 3 to 5 mL NS into each injection site. Do not administer intravenously. |
Refer to Prevention and Management of Infiltration and Extravasation Policy and Guidelines for Antidote Administration on PHSA SHOP for a complete listing of agents for which hyaluronidase treatment may be useful and for further information on management of extravasation. Most benefit if injected within 1 hour of extravasation. Standard Prescription: hyaluronidase 150 units/mL in NS: inject sc/intradermally around extravasation site per protocol |